Response to McGirr et al.'s Comment on “Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada”

Wilson, M. R., Wasserman, M., Jadavji, T., Postma, M., Breton, M. C., Peloquin, F., … Farkouh, R. (2018, December 1). Response to McGirr et al.’s Comment on “Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada.” Infectious Diseases and Therapy. Springer Healthcare. https://doi.org/10.1007/s40121-018-0221-2